Relmada Therapeutics Inc. (RLMD) stock prices were down 3.26% some time after market trading commenced on July 27th, 2021, bringing the price per share down to USD$24.30 early on in the trading day.
Positive REL-1017 Topline Data
July 27th 2021 announced the top-line results of the human abuse potential study with REL-1017, the company’s lead candidate. The novel NMDA receptor channel blocker is in Phase 3 development for the treatment of the major depressive disorder (MDD). Top-line results indicated all three doses of REL-1017 tested in recreational opioid users demonstrated a highly statistically significant difference from the control group. The 25mg, 75mg, and 150mg therapeutic, supratherapeutic, and maximum tolerated doses were compared to the active control drug, oxycodone 40 mg.
RLMD Stock’s Study Endpoints
The primary endpoint of the study was a measure of ‘likability’ with the subjects rating the maximum effect for Drug Liking “at the moment” using a 1=100 bipolar rating scale. The visual analog scale (VAS) has 100 as the highest likeability, 50 as the neutral, and the 0 as the highest dislike. The data clearly shows a very meaningful difference between the REL-1017 treatment and oxycodone at all three tested doses.
Safety of REL-1017
The results consolidate previous findings about the lack of opioid effects of REL-1017. RLMD stock is keen to continue the clinical development of REL-1017 as a novel, safe, and rapidly effective treatment for MDD. The findings have been consistent with RLMD stock’s development programs and confirms what has already been established by an extensive body of literature that indicates the lack of abuse potential of REL-1017. The results strongly support the ongoing REL-1017 late-stage development program.
Consolidated Scope for RLMD Stock
The results are in line with HAP results that have been seen for other drugs that affect the CNS and have been scheduled at Classes IV or V, or remain unscheduled, during the assessment and review period. RLMD stock is keen to address the large unmet need for patients suffering from depression in the absence of safe and rapidly effective treatments.
Future Outlook for RLMD
Armed with the promising topline results from its study of REL-1017, RLMD is poised to capitalize on the enormous marketspace it finds needing to be addressed. Current and potential investors are hopeful that management will be able to leverage the resources at their diposal to facilitate significant and sustained increases in shareholder value.
